Watch these on-demand webinars to learn how Thermo Fisher Scientific is the leading single-source supplier for your COVID-19 testing needs.
Molecular Multi-Target Assay Design with SARS-CoV-2 Mutations in Mind
Emerging SARS-CoV-2 Mutations: Impact on TaqPath Assay Performance and its Clinical Implications
Product introduction and performance
Putting the Applied Biosystems TaqPath™ COVID-19 kit to the test: clinical performance against the competition
Dr. Ninad Mehta, Medical Microbiology, ARUP Laboratories
Responding to the COVID-19 Outbreak: Global Clinical Performance and Development of the Applied Biosystems TaqPath COVID-19 Assay
Peter Silvester, Senior Vice President and President, Life Sciences Solutions Group – Thermo Fisher Scientific
Paul A. Granato, Ph.D., DABMM, FAAM, Professor Emeritus of Pathology at SUNY Upstate Medical University Director of Microbiology at Laboratory Alliance of Central New York
Clinical Laboratory Experience with TaqPath COVID-19 Testing
Scott Hunicke-Smith, PhD
Scientific Director, Clinical Pathology Laboratories
The worldwide spread of COVID-19 has stressed clinical laboratories in numerous dimensions including supply chain management, preanalytical throughput, analytical throughput, and extreme variances in testing demand. Innovative tests, such as the TaqPath COVID-19 Combo Kit, build on the strong technical foundation and substantial manufacturing capacity of Thermo Fisher Scientific while also leveraging the workforce of molecular biologists trained and experienced in real-time PCR techniques in order to address an unprecedented scale-up in test capacity required. Whether in a start-up laboratory or a well-established laboratory, successful ongoing testing with the TaqPath COVID-19 Combo Kit that is responsive to the needs of patients and physicians requires acute attention to detail in traditional areas of laboratory operations including quality control, workflow, labor allocation, standardized processes, and technician training, but the open format of the assay and associated analyses add additional challenges. This presentation will illustrate how the TaqPath COVID-19 Combo Kit is operationalized at a large regional reference laboratory with particular emphasis on the challenges unique to the assay.
TaqPath COVID-19 Combo Kit: A highly sensitive, specific, and robust real-time PCR test
Andrew Brooks, PhD
Professor of Genetics Rutgers University; COO RUCDR Infinite Biologics; CSO Brooks Life Sciences
Vijay Singh, PhD
Managing Principal Scientist, Molecular Diagnostics, HealthTrack, Rx
In late 2019, researchers identified the SARS-CoV-2 pathogen as the virus responsible for COVID-19. The virus spread rapidly throughout the world and was declared a global health concern by the World Health Organization. At the end of January 2020, Thermo Fisher Scientific launched a SARS-CoV-2 pathogen detection assay, which was quickly developed into a multiplex kit containing highly specific assays and controls targeting three different regions of the SARS-CoV-2 genome. The kit was approved for Emergency Use Authorization (EUA) by the United States Food and Drug Administration in March, and has since been used as a central component of other EUA approved protocols.
High throughput diagnostic testing
Announcing Thermo Fisher Scientific's Amplitude Solution: High-Throughput, Highly Automated COVID-19 Testing
Hannah Pezzi, PhD
Staff Scientist, Genetic Testing Solutions, Thermo Fisher Scientific
With the on-going COVID-19 crisis, we now know that testing volumes must increase in order to help restore our communities back to some degree of normality. But questions remain: How can labs scale while minimizing costs? How can they be assured of uninterrupted supply of tests and reagents? In this webinar, we introduce the upcoming Thermo Fisher Scientific Amplitude Solution—a highly-automated molecular diagnostic testing system that can analyze over 6,000 specimens in a single day with the reliability and confidence of assured assay and reagent supply, along with 24/7 world class service and support.
COVID-19 diagnostic testing is a valuable component of safety protocols
- Learn about the difference between diagnostic and antibody testing
- Gain understanding of different testing modalities to understand what would work best for your organization
- Discuss the value and rationale for implementing testing in the workplace
- Hear about Thermo Fisher's and Everlywell’s end-to-end testing solution
Safety and well-being in the workplace
- Discuss the value and rationale for implementing COVID-19 testing in the workplace
- Hear real-world strategies on workplace testing and policies
- Gain understanding of Everlywell's turn-key resources for sample collection, test reporting, and result-related actions
- Share insights on best practices for communicating and implementing a testing program
COVID-19 epidemiology and workplace testing strategies
- Describe screening and surveillance approaches to help guide back-to-work task forces
- Discuss the latest understanding of SARS-CoV-2 infection in an individual and in a population
Intended use and regulatory statements of products vary. For specific intended use and regulatory statements please refer to the Instructions for Use (IFU). Product availability by country varies. For product availability in your country.